Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell-based cellular therapies, today announced a $62 million Series B fina ...

Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell therapies, launched today with an oversubscribed Series A financing.

Avanish Vellanki will lead Garuda Therapeutics into a new era of developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases ...

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Garuda Therapeutics (Garuda), a biotechnology company creating off-the-shelf, HSC therapies for a multitude of blood disorders, today announced ...

Stratus Therapeutics is the only company developing on-demand Prime HSCs™ and Prime HPCs™ to restore the blood and immune system without the need to identify a donor. Its lead product, ST-101 ...

About Garuda Garuda Therapeutics seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants.

Now focusing his expertise in advisory, non-executive roles, Laurence sits on the Board of several companies, including KalVista Pharmaceuticals, Garuda Therapeutics and Broken String Biosciences.

CAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Garuda Therapeutics (Garuda), a biotechnology company pioneering off-the-shelf, blood stem cell therapies, today announced that its Board of ...